Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of stage IV NSCLC with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement (1). The gene discussed is ALK; the disease is non-small cell lung carcinoma.